{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T06:22:36Z","timestamp":1794291756457,"version":"4.9.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T00:00:00Z","timestamp":1599436800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T00:00:00Z","timestamp":1599436800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Endocrine therapy (ET)-based regimens are the mainstay of treatment for patients with hormone receptor-positive\/human epidermal growth factor receptor 2-negative (HR+\/HER2\u2212) advanced breast cancer. With the introduction of new treatment classes, it is important to examine patient symptoms and health-related quality of life (HRQoL) at the start of this changing therapeutic landscape. This real-world study describes the patient-reported outcomes (PROs) of women with HR+\/HER2\u2212 advanced breast cancer receiving ET-based regimens who were na\u00efve to systemic treatment in the advanced setting across five European countries (EU5).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Data were collected between March and July 2017 from surveyed oncologists and their patients at a single time point using the multinational Adelphi Advanced Breast Cancer Disease Specific Programme\u2122. Patients completed PRO questionnaires on HRQoL (EORTC QLQ-C30), pain severity and interference, and work and activity impairment. A multiple linear regression model explored factors associated with HRQoL.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Across EU5, 226 physicians provided data on 781 women with HR+\/HER2\u2212 advanced breast cancer taking their first ET-based regimen for advanced disease, of whom 252 provided PRO data. This subset had a mean age of 67.1\u2009years, 94% were postmenopausal, 89% were diagnosed with advanced breast cancer at initial presentation, 79% had stage IV disease (66% of these patients had bone metastases and 38% had visceral metastases, including 18% with liver metastases) and 77% were on endocrine-only therapy as their initial treatment for advanced disease. The mean EORTC QLQ-C30 global health score (50.9) was worse than the reference value for patients with advanced breast cancer (60.2). Fatigue, pain, and insomnia were the most severe symptoms, and mean functioning scores were also worse than reference values. \u201cWorst pain\u201d and \u201cpain interference\u201d were moderate\/severe for 42 and 80% of patients. Mean activity impairment was 44%, and greater activity impairment was associated with poorer HRQoL.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Despite receiving first-line ET-based regimens for advanced disease, these women had a poor HRQoL and high levels of symptoms, pain, pain interference and activity impairment. New treatments that maintain a stable disease state and reduce activity impairment may have a positive effect on the HRQoL of those living with advanced breast cancer.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12885-020-07294-2","type":"journal-article","created":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T10:43:35Z","timestamp":1600080215000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Real-world patient-reported outcomes of women receiving initial endocrine-based therapy for HR+\/HER2\u2212 advanced breast cancer in five European countries"],"prefix":"10.1186","volume":"20","author":[{"given":"Alison","family":"Davie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gebra Cuyun","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Rider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Pike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory L.","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Ringeisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Pivot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,7]]},"reference":[{"key":"7294_CR1","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.ejca.2018.07.005","volume":"103","author":"J Ferlay","year":"2018","unstructured":"Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M, Gavin A, Visser O, Bray F. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018;103:356\u201387. https:\/\/doi.org\/10.1016\/j.ejca.2018.07.005.","journal-title":"Eur J Cancer"},{"key":"7294_CR2","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394\u2013424.","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"7294_CR3","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1038\/bjc.2013.6","volume":"108","author":"S Walters","year":"2013","unstructured":"Walters S, Maringe C, Butler J, Rachet B, Barrett-Lee P, Bergh J, et al. Breast cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK, 2000-2007: a population-based study. Br J Cancer. 2013;108(5):1195\u2013208. https:\/\/doi.org\/10.1038\/bjc.2013.6.","journal-title":"Br J Cancer"},{"issue":"6","key":"7294_CR4","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1177\/1758834015608993","volume":"7","author":"T Reinert","year":"2015","unstructured":"Reinert T, Barrios CH. Optimal management of hormone receptor positive metastatic breast cancer in 2016. Ther Adv Med Oncol. 2015;7(6):304\u201320.","journal-title":"Ther Adv Med Oncol"},{"issue":"3","key":"7294_CR5","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s10549-013-2711-y","volume":"141","author":"DJ Lobbezoo","year":"2013","unstructured":"Lobbezoo DJ, van Kampen RJ, Voogd AC, Wouter Dercksen M, van den Berkmortel F, Smilde TJ, et al. Prognosis of metastatic breast cancer subtypes: the hormone receptor\/HER2- positive subtype is associated with the most favourable outcome. Breast Cancer Res Treat. 2013;141(3):507\u201314.","journal-title":"Breast Cancer Res Treat"},{"key":"7294_CR6","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.ctrv.2017.12.002","volume":"63","author":"GA Ba\u015faran","year":"2018","unstructured":"Ba\u015faran GA, Twelves C, Di\u00e9ras V, Cortes J, Awada A. Ongoing unmet needs in treating estrogen receptor-positive\/HER2-negative metastatic breast cancer. Cancer Treat Rev. 2018;63:144\u201355.","journal-title":"Cancer Treat Rev"},{"key":"7294_CR7","doi-asserted-by":"publisher","first-page":"45411","DOI":"10.1038\/srep45411","volume":"7","author":"Y Gong","year":"2017","unstructured":"Gong Y, Liu YR, Ji P, Hu X, Shao ZM. Impact of molecular subtypes on metastatic breast cancer patients: a SEER population-based study. Sci Rep. 2017;7:45411. https:\/\/doi.org\/10.1038\/srep45411.","journal-title":"Sci Rep"},{"issue":"8","key":"7294_CR8","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1093\/annonc\/mdy192","volume":"29","author":"F Cardoso","year":"2018","unstructured":"Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, Andr\u00e9 F, et al. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4). Ann Oncol. 2018;29(8):1634\u201357. https:\/\/doi.org\/10.1093\/annonc\/mdy192.","journal-title":"Ann Oncol"},{"issue":"5","key":"7294_CR9","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1111\/j.1365-2354.2012.01370.x","volume":"21","author":"E Reed","year":"2012","unstructured":"Reed E, Kossler I, Hawthorn J. Quality of life assessments in advanced breast cancer: should there be more consistency? Eur J Cancer Care (Engl). 2012;21(5):565\u201380.","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"7","key":"7294_CR10","doi-asserted-by":"publisher","first-page":"e294","DOI":"10.1016\/S1470-2045(16)30099-7","volume":"17","author":"I Ghislain","year":"2016","unstructured":"Ghislain I, Zikos E, Coens C, Quinten C, Balta V, Tryfonidis K, et al. Health-related quality of life in locally advanced and metastatic breast cancer: methodological and clinical issues in randomised controlled trials. Lancet Oncol. 2016 Jul;17(7):e294\u2013304. https:\/\/doi.org\/10.1016\/S1470-2045(16)30099-7.","journal-title":"Lancet Oncol."},{"issue":"9","key":"7294_CR11","doi-asserted-by":"publisher","first-page":"e459","DOI":"10.1016\/S1470-2045(18)30418-2","volume":"19","author":"M Pe","year":"2018","unstructured":"Pe M, Dorme L, Coens C, Basch E, Calvert M, Campbell A, et al. Statistical analysis of patient-reported outcome data in randomised controlled trials of locally advanced and metastatic breast cancer: a systematic review. Lancet Oncol. 2018;19(9):e459\u201369. https:\/\/doi.org\/10.1016\/S1470-2045(18)30418-2.","journal-title":"Lancet Oncol"},{"issue":"6","key":"7294_CR12","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.breast.2014.08.004","volume":"23","author":"CS Cleeland","year":"2014","unstructured":"Cleeland CS, Mayer M, Dreyer NA, Yim YM, Yu E, Su Z, et al. Impact of symptom burden on work-related abilities in patients with locally recurrent or metastatic breast cancer: Results from a substudy of the VIRGO observational cohort study. Breast. 2014;23(6):763\u20139.","journal-title":"Breast."},{"issue":"6","key":"7294_CR13","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1586\/14737167.2014.949243","volume":"14","author":"S Gupta","year":"2014","unstructured":"Gupta S, Zhang J, Jerusalem G. The association of chemotherapy versus hormonal therapy and health outcomes among patients with hormone receptor-positive, HER2-negative metastatic breast cancer: Experience from the patient perspective. Expert Rev Pharmacoecon Outcomes Res. 2014;14(6):929\u201340.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"7294_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2017-000227","volume":"2","author":"R Wood","year":"2017","unstructured":"Wood R, Mitra D, de Courcy J, Iyer S. Patient-reported pain severity, pain interference and health status in HR+\/HER2- advanced\/metastatic breast cancer. ESMO Open. 2017;2:e000227. https:\/\/doi.org\/10.1136\/esmoopen-2017-000227.","journal-title":"ESMO Open"},{"issue":"8","key":"7294_CR15","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1016\/j.clinthera.2017.07.009","volume":"39","author":"R Wood","year":"2017","unstructured":"Wood R, Mitra D, de Courcy J, Iyer S. Patient-reported quality of life and treatment satisfaction in patients with HR+\/HER2- advanced\/metastatic breast cancer. Clin Ther. 2017;39(8):1719\u201328.","journal-title":"Clin Ther"},{"issue":"4","key":"7294_CR16","doi-asserted-by":"publisher","first-page":"e282","DOI":"10.3747\/co.25.3765","volume":"25","author":"V Lambert-Obry","year":"2018","unstructured":"Lambert-Obry V, Gouault-Lalibert\u00e9 A, Castonguay A, Zanotti G, Tran T, Mates M, et al. Real-world patient- and caregiver-reported outcomes in advanced breast cancer. Curr Oncol. 2018;25(4):e282\u201390.","journal-title":"Curr Oncol"},{"key":"7294_CR17","doi-asserted-by":"crossref","unstructured":"DeLaurentiis M, Davis KL, Ajmera M, Mitra D, Nuzzo CMA, Harbeck N. Health-related quality of life in women with HR+\/HER2- advanced or metastatic breast cancer treated in real world settings in Italy and Germany. Poster presented at ESMO 43rd Congress Oct 22, 2018.","DOI":"10.1093\/annonc\/mdy272.324"},{"key":"7294_CR18","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s40487-016-0033-z","volume":"4","author":"R Caldeira","year":"2016","unstructured":"Caldeira R, Scazafave M. Real-world treatment patterns for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in Europe and the United States. Oncol Ther. 2016;4:189\u201397.","journal-title":"Oncol Ther"},{"issue":"11","key":"7294_CR19","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1185\/03007990802457040","volume":"24","author":"P Anderson","year":"2008","unstructured":"Anderson P, Benford M, Harris N, Karavali M, Piercy J. Real-world physician and patient behaviour across countries: Disease-Specific Programmes - a means to understand. Curr Med Res Opin. 2008;24(11):3063\u201372.","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"7294_CR20","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365\u201376.","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"7294_CR21","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1200\/JCO.1996.14.10.2756","volume":"14","author":"MA Sprangers","year":"1996","unstructured":"Sprangers MA, Groenvold M, Arraras JI, Franklin J, te Velde A, Muller M, et al. The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol. 1996;14(10):2756\u201368.","journal-title":"J Clin Oncol"},{"key":"7294_CR22","volume-title":"EORTC QLQ-C30 scoring manual","author":"P Fayers","year":"2001","unstructured":"Fayers P, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A. EORTC QLQ-C30 scoring manual. 3rd ed. Brussels: European Organisation for Research and Treatment of Cancer; 2001.","edition":"3"},{"issue":"5","key":"7294_CR23","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3109\/07853890109002087","volume":"33","author":"R Rabin","year":"2001","unstructured":"Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33(5):337\u201343.","journal-title":"Ann Med"},{"key":"7294_CR24","volume-title":"EQ-5D value sets: inventory, comparative review and user guide","year":"2007","unstructured":"Szende A, Oppe M, Devlin N, editors. EQ-5D value sets: inventory, comparative review and user guide. Dordrecht: Springer Netherlands; 2007."},{"issue":"2","key":"7294_CR25","first-page":"129","volume":"23","author":"CS Cleeland","year":"1994","unstructured":"Cleeland CS, Ryan KM. Pain assessment: global use of the brief pain inventory. Ann Acad Med Singap. 1994;23(2):129\u201338.","journal-title":"Ann Acad Med Singap"},{"issue":"5","key":"7294_CR26","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353\u201365.","journal-title":"Pharmacoeconomics."},{"key":"7294_CR27","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/0304-3959(94)00178-H","volume":"61","author":"RC Serlin","year":"1995","unstructured":"Serlin RC, Mendoza TR, Nakamura Y, Edwards KR, Cleeland CS. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain. 1995;61:277\u201384.","journal-title":"Pain."},{"key":"7294_CR28","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1002\/cncr.27789","volume":"119","author":"CS Cleeland","year":"2013","unstructured":"Cleeland CS, Body J-J, Stopeck A, von Moos R, Fallowfield L, Mathias SD, et al. Pain outcomes in patients with advanced breast cancer and bone metastases. Cancer. 2013;119:832\u20138.","journal-title":"Cancer."},{"issue":"6","key":"7294_CR29","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1097\/j.pain.0000000000000890","volume":"158","author":"Q Shi","year":"2017","unstructured":"Shi Q, Mendoza TR, Dueck AC, Ma H, Zhang J, Qian Y, Bhowmik D, Cleeland CS. Determination of mild, moderate, and severe pain interference in patients with cancer. Pain. 2017;158(6):1108\u201312. https:\/\/doi.org\/10.1097\/j.pain.0000000000000890.","journal-title":"Pain."},{"key":"7294_CR30","volume-title":"The behavior of maximum likelihood estimates under nonstandard conditions. Proceedings of the Fifth Berkeley Symposium on Mathematical Statistics and Probability, Volume 1: Statistics, 221\u2013233","author":"PJ Huber","year":"1967","unstructured":"Huber PJ. The behavior of maximum likelihood estimates under nonstandard conditions. Proceedings of the Fifth Berkeley Symposium on Mathematical Statistics and Probability, Volume 1: Statistics, 221\u2013233. Berkeley: University of California Press; 1967."},{"key":"7294_CR31","doi-asserted-by":"publisher","first-page":"817","DOI":"10.2307\/1912934","volume":"48","author":"H White","year":"1980","unstructured":"White H. A heteroskedasticity-consistent covariance matrix estimator and a direct test for heteroskedasticity. Econometrica. 1980;48:817\u201338.","journal-title":"Econometrica."},{"key":"7294_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2307\/1912526","volume":"50","author":"H White","year":"1982","unstructured":"White H. Maximum likelihood estimation of misspecified models. Econometrica. 1982;50:1\u201325.","journal-title":"Econometrica."},{"key":"7294_CR33","unstructured":"European Pharmaceutical Market Research Association (EphMRA) code of conduct. Updated January 2017. http:\/\/www.ephmra.org\/Code-of-Conduct-Support. Accessed 14 Nov 2018."},{"key":"7294_CR34","unstructured":"ICC\/ESOMAR. International code on market and social research 2007. https:\/\/www.esomar.org\/uploads\/public\/knowledge-and-standards\/codes-and-guidelines\/ICCESOMAR_Code_English_.pdf. Accessed 6 Feb 2018."},{"key":"7294_CR35","volume-title":"EORTC QLQ-C30 reference values","author":"NW Scott","year":"2008","unstructured":"Scott NW, Fayers PM, Aaronson NK, Bottomley A, de Graeff A, Groenvold M, et al. EORTC QLQ-C30 reference values. Brussels: European Organisation for Research and treatment of Cancer; 2008."},{"key":"7294_CR36","doi-asserted-by":"publisher","first-page":"958","DOI":"10.3109\/0284186X.2013.879998","volume":"53","author":"A Hinz","year":"2014","unstructured":"Hinz A, Singer S, Br\u00e4hler E. European reference values for the quality of life questionnaire EORTC QLQ-C30: Results of a German investigation and a summarizing analysis of six European general population normative studies. Acta Oncol. 2014;53:958\u201365.","journal-title":"Acta Oncol"},{"issue":"2","key":"7294_CR37","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-023568","volume":"9","author":"D P\u00e9rol","year":"2019","unstructured":"P\u00e9rol D, Robain M, Arveux P, Mathoulin-P\u00e9lissier S, Chamorey E, Asselain B, et al. The ongoing French metastatic breast cancer (MBC) cohort: the example-based methodology of the Epidemiological Strategy and Medical Economics (ESME). BMJ Open. 2019;9(2):e023568. https:\/\/doi.org\/10.1136\/bmjopen-2018-023568.","journal-title":"BMJ Open"},{"key":"7294_CR38","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jcpo.2015.03.002","volume":"5","author":"SA Narod","year":"2015","unstructured":"Narod SA, Iqbal J, Miller AB. Why have breast cancer mortality rates declined? J Cancer Policy. 2015;5:8\u201317.","journal-title":"J Cancer Policy"},{"issue":"4","key":"7294_CR39","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.clinthera.2018.03.004","volume":"40","author":"R Ayyagari","year":"2018","unstructured":"Ayyagari R, Tang D, Patterson-Lomba O, Zhou Z, Xie J, Chandiwana D, Dalal AA, Niravath PA. Progression-free survival with first-line endocrine-based therapies among postmenopausal women with HR+\/HER2- metastatic breast cancer: A network meta-analysis. Clin Ther. 2018;40(4):628\u201339.e3. https:\/\/doi.org\/10.1016\/j.clinthera.2018.03.004.","journal-title":"Clin Ther"},{"issue":"1","key":"7294_CR40","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1007\/s12282-016-0687-2","volume":"24","author":"K Kokkonen","year":"2017","unstructured":"Kokkonen K, Saarto T, Makinen T, et al. The functional capacity and quality of life of women with advanced breast cancer. Breast Cancer. 2017;24(1):128\u201336.","journal-title":"Breast Cancer"},{"issue":"5","key":"7294_CR41","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1080\/0284186X.2017.1400683","volume":"57","author":"M Rautalin","year":"2018","unstructured":"Rautalin M, F\u00e4rkkil\u00e4 N, Sintonen H, Saarto T, Taari K, Jahkola T, Roine RP. Health-related quality of life in different states of breast cancer - comparing different instruments. Acta Oncol. 2018;57(5):622\u20138. https:\/\/doi.org\/10.1080\/0284186X.2017.1400683.","journal-title":"Acta Oncol"},{"issue":"10","key":"7294_CR42","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1055\/s-0036-1593233","volume":"76","author":"M Wallwiener","year":"2016","unstructured":"Wallwiener M, Simoes E, Sokolov AN, Brucker SY, Fasching PA, Graf J. Health-related quality of life in metastatic and adjuvant breast cancer patients. Geburtshilfe Frauenheilkd. 2016;76(10):1065\u201373.","journal-title":"Geburtshilfe Frauenheilkd"},{"issue":"3","key":"7294_CR43","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/tbj.12107","volume":"19","author":"CE Mosher","year":"2013","unstructured":"Mosher CE, Johnson C, Dickler M, Norton L, Massie MJ, DuHamel K. Living with metastatic breast cancer: a qualitative analysis of physical, psychological, and social sequelae. Breast J. 2013;19(3):285\u201392. https:\/\/doi.org\/10.1111\/tbj.12107.","journal-title":"Breast J"},{"issue":"1","key":"7294_CR44","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s41687-019-0098-1","volume":"3","author":"N Galipeau","year":"2019","unstructured":"Galipeau N, Klooster B, Krohe M, Tang DH, Revicki DA, Cella D. Understanding key symptoms, side effects, and impacts of HR+\/HER2- advanced breast cancer: qualitative study findings. J Patient Rep Outcomes. 2019 Feb 7;3(1):10. https:\/\/doi.org\/10.1186\/s41687-019-0098-1.","journal-title":"J Patient Rep Outcomes"},{"issue":"12","key":"7294_CR45","doi-asserted-by":"publisher","first-page":"758","DOI":"10.6061\/clinics\/2017(12)07","volume":"72","author":"WA Costa","year":"2017","unstructured":"Costa WA, Monteiro MN, Queiroz JF, Goncalves AK. Pain and quality of life in breast cancer patients. Clinics (Sao Paulo). 2017;72(12):758\u201363.","journal-title":"Clinics (Sao Paulo)"},{"issue":"3","key":"7294_CR46","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s10549-015-3420-5","volume":"151","author":"PJ Hollen","year":"2015","unstructured":"Hollen PJ, Msaouel P, Gralla RJ. Determining issues of importance for the evaluation of quality of life and patient-reported outcomes in breast cancer: results of a survey of 1072 patients. Breast Cancer Res Treat. 2015;151(3):679\u201386.","journal-title":"Breast Cancer Res Treat"},{"issue":"17","key":"7294_CR47","doi-asserted-by":"publisher","first-page":"27990","DOI":"10.18632\/oncotarget.15856","volume":"8","author":"Q Wu","year":"2017","unstructured":"Wu Q, Li J, Zhu S, Wu J, Chen C, Liu Q, Wei W, Zhang Y, Sun S. Breast cancer subtypes predict the preferential site of distant metastases: a SEER based study. Oncotarget. 2017;8(17):27990\u20136. https:\/\/doi.org\/10.18632\/oncotarget.15856.","journal-title":"Oncotarget"},{"key":"7294_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jbo.2017.11.004","volume":"11","author":"R von Moos","year":"2018","unstructured":"von Moos R, Body JJ, Rider A, de Courcy J, Bhowmik D, Gatta F, Hechmati G, Qian Y. Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in real-world practice in six European countries. J Bone Oncol. 2018;11:1\u20139.","journal-title":"J Bone Oncol"},{"key":"7294_CR49","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41523-018-0094-2","volume":"4","author":"A Di Leo","year":"2018","unstructured":"Di Leo A, O'Shaughnessy J, Sledge GW Jr, et al. Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy. NPJ Breast Cancer. 2018;4:41. https:\/\/doi.org\/10.1038\/s41523-018-0094-2 eCollection 2018.","journal-title":"NPJ Breast Cancer"},{"issue":"Suppl 2","key":"7294_CR50","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s00761-018-0358-3","volume":"24","author":"BE Maissenhaelter","year":"2018","unstructured":"Maissenhaelter BE, Woolmore AL, Schlag PM. Real-world evidence research based on big data: Motivation-challenges-success factors. Onkologe (Berl). 2018;24(Suppl 2):91\u20138.","journal-title":"Onkologe (Berl)"},{"issue":"10","key":"7294_CR51","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1080\/03007995.2016.1205005","volume":"32","author":"DM Turner-Bowker","year":"2016","unstructured":"Turner-Bowker DM, Hao Y, Foley C, Galipeau N, Mazar I, Krohe M, et al. The use of patient-reported outcomes in advanced breast cancer trials: a review of the published literature. Curr Med Res Opin. 2016;32(10):1709\u201317.","journal-title":"Curr Med Res Opin"},{"key":"7294_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jclinepi.2019.10.003","volume":"118","author":"JM Giesinger","year":"2020","unstructured":"Giesinger JM, Loth FLC, Aaronson NK, Arraras JI, Caocci G, Efficace F, Groenvold M, van Leeuwen M, Petersen MA, Ramage J, Tomaszewski KA, Young T, Holzner B. EORTC Quality of Life Group. Thresholds for clinical importance were established to improve interpretation of the EORTC QLQ-C30 in clinical practice and research. J Clin Epidemiol. 2020;118:1\u20138.","journal-title":"J Clin Epidemiol"},{"key":"7294_CR53","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","volume":"16","author":"D Osoba","year":"1998","unstructured":"Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998;16:139\u201344.","journal-title":"J Clin Oncol"},{"key":"7294_CR54","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1016\/j.ejca.2012.02.059","volume":"48","author":"K Cocks","year":"2012","unstructured":"Cocks K, King MT, Velikova G, de Castro G Jr, Martyn St-James M, Fayers PM, Brown JM. Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. Eur J Cancer. 2012;48:1713\u201321.","journal-title":"Eur J Cancer"},{"key":"7294_CR55","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s10549-018-4769-z","volume":"170","author":"S Verma","year":"2018","unstructured":"Verma S, O'Shaughnessy J, Burris HA, Campone M, Alba E, Chandiwana D, Dalal AA, Sutradhar S, Monaco M, Janni W. Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib\u2009+\u2009letrozole: results from MONALEESA-2. Breast Cancer Res Treat. 2018;170:535\u201345.","journal-title":"Breast Cancer Res Treat"},{"key":"7294_CR56","doi-asserted-by":"publisher","first-page":"pkz037","DOI":"10.1093\/jncics\/pkz037","volume":"3","author":"JZ Musoro","year":"2019","unstructured":"Musoro JZ, Coens C, Fiteni F, et al. Minimally important differences for interpreting EORTC QLQ-C30 scores in patients with advanced breast cancer. JNCI Cancer Spectrum. 2019;3:pkz037. https:\/\/doi.org\/10.1093\/jncics\/pkz037.","journal-title":"JNCI Cancer Spectrum"},{"issue":"2","key":"7294_CR57","doi-asserted-by":"publisher","first-page":"e243","DOI":"10.1634\/theoncologist.2019-0551","volume":"25","author":"PA Kaufman","year":"2020","unstructured":"Kaufman PA, Toi M, Neven P, Sohn J, Grischke EM, Andre V, Stoffregen C, Shekarriz S, Price GL, Carter GC, Sledge GW Jr. Health-related quality of life in MONARCH 2: Abemaciclib plus Fulvestrant in hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy. Oncologist. 2020;25(2):e243\u201351. https:\/\/doi.org\/10.1634\/theoncologist.2019-0551.","journal-title":"Oncologist."},{"key":"7294_CR58","doi-asserted-by":"publisher","first-page":"67","DOI":"10.14694\/EDBK_159514","volume":"35","author":"PG Kluetz","year":"2016","unstructured":"Kluetz PG, Chingos DT, Basch EM, Mitchell SA. Patient-reported outcomes in cancer clinical trials: measuring symptomatic adverse events with the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Am Soc Clin Oncol Educ Book. 2016;35:67\u201373. https:\/\/doi.org\/10.14694\/EDBK_159514.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"7294_CR59","doi-asserted-by":"publisher","first-page":"171","DOI":"10.2147\/PROM.S178344","volume":"10","author":"EM Chang","year":"2019","unstructured":"Chang EM, Gillespie EF, Shaverdian N. Truthfulness in patient-reported outcomes: factors affecting patients\u2019 responses and impact on data quality. Patient Relat Outcome Meas. 2019;10:171\u201386.","journal-title":"Patient Relat Outcome Meas"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07294-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-020-07294-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07294-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T23:11:55Z","timestamp":1630969915000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-07294-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,7]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["7294"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-07294-2","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,7]]},"assertion":[{"value":"25 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Advanced Breast Cancer DSP followed European Pharmaceutical Marketing Research Association guidelines [] and adhered to the ICC\/ESOMAR International Code on observational research []. The study protocol was reviewed and approved by the FEKI institutional review board. All patients included in the DSP provided written informed consent to participate. All data were anonymized and aggregated prior to receipt by Adelphi Real World for analysis.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"A.D., G.C.C., and G.P. have disclosed that they are employees of Eli Lilly and Company. F.R. was an employee of Eli Lilly and Company during the development of the analysis.A.B., A.R., J.P., and K.L. have disclosed that they are employees of Adelphi Real World Ltd., who own the multi-sponsored Disease Specific Programme, and were paid by Eli Lilly and Company Ltd. in the development of this analysis and manuscript.X.P. has disclosed an advisory role with Eli Lilly and Company; for which an honorarium was received from Eli Lilly and Company Ltd. for consultancy support in the development of this analysis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"855"}}